Metrizamide in radiography of the central nervous system. A preliminary report.
Metrizamide seems to be a suitable contrast medium for ventriculography and myelography. This contrast medium is less toxic and far less epileptogenic and spasmogenic than the other water-soluble contrast media in current use. No serious complications were noted in the present series. Transient changes in EEG were recorded, mainly with cervical myelographies. However, it is too early to evaluate the long-term side effects.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002535:Cerebral Aqueduct / Q000000981:diagnostic imaging; D002551:Cerebral Ventricle Neoplasms / Q000000981:diagnostic imaging; D014695:Cerebral Ventriculography; D002648:Child; D002675:Child, Preschool; D003287:Contrast Media / Q000009:adverse effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007405:Intervertebral Disc Displacement / Q000000981:diagnostic imaging; D008793:Metrizamide / Q000009:adverse effects; D008875:Middle Aged; D009192:Myelography; D009362:Neoplasm Metastasis; D009442:Neurilemmoma / Q000000981:diagnostic imaging; D010870:Pineal Gland / Q000000981:diagnostic imaging; D013120:Spinal Cord Neoplasms / Q000000981:diagnostic imaging; D013724:Teratoma / Q000000981:diagnostic imaging
D003287:Contrast Media; D008793:Metrizamide